The arrival of GLP-1 weight-loss medications has transformed the conversation around obesity, offering results that once seemed impossible without surgery. But alongside their rapid rise, a new trend has quietly emerged: patients taking far smaller doses than those officially recommended. In this episode, we explore the growing practice of microdosing GLP-1 medications, tracing why some people reduce their doses under medical supervision while others experiment on their own in search of lower costs and fewer side effects. From improvised dosing techniques and unanswered scientific questions to the challenges of balancing effectiveness, safety, and affordability, we examine why this practice has become both appealing and controversial. The story reveals a broader tension at the heart of modern medicine, where patient innovation is racing ahead of  ...